Olfactory immune response to SARS-CoV-2
SA Wellford, EA Moseman - Cellular & Molecular Immunology, 2024 - nature.com
Numerous pathogens can infect the olfactory tract, yet the pandemic caused by SARS-CoV-
2 has strongly emphasized the importance of the olfactory mucosa as an immune barrier …
2 has strongly emphasized the importance of the olfactory mucosa as an immune barrier …
[HTML][HTML] Neurological complications after COVID-19: A systematic literature review
G Molaverdi, Z Kamal, M Safavi, A Shafiee… - Eneurologicalsci, 2023 - Elsevier
COVID-19 is primarily classified as a respiratory disorder; however, various neurological
symptoms have been reported in COVID-19 patients. Neurological manifestations may be …
symptoms have been reported in COVID-19 patients. Neurological manifestations may be …
Protein drug delivery using a novel maxillofacial technique targeting the visual pathway in the brain, the optic nerve, and the retina
R Rajendran, JP Arunachalam… - ACS Chemical …, 2023 - ACS Publications
Protein drugs are used for treating many diseases of the eye and the brain. The formidable
blood neural barriers prevent the delivery of these drugs into the eye and the brain. Hence …
blood neural barriers prevent the delivery of these drugs into the eye and the brain. Hence …
SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors
A critical step in the drug design for SARS-CoV-2 is to discover its molecular targets. This
study comprehensively reviewed the molecular mechanisms of SARS-CoV-2, exploring host …
study comprehensively reviewed the molecular mechanisms of SARS-CoV-2, exploring host …
[HTML][HTML] The Administration of Levodopa in a Patient With Parkinson's Disease Using a Novel Maxillofacial Route: A First-in-Human Report
S Thirunavukarasu, BBV Ramanan, SK Suresh… - Cureus, 2023 - ncbi.nlm.nih.gov
Parkinson's disease is characterized by the loss of nigrostriatal dopaminergic neurons in the
brain. Dopamine cannot be administered systemically because it does not cross the blood …
brain. Dopamine cannot be administered systemically because it does not cross the blood …
NRP1 and furin as putative mediators of SARS-CoV-2 entry into human brain cells
Abstract Background: Coronavirus disease 2019 (COVID-19) has prominent neurological
manifestations, including psychiatric symptoms, indicating a significant synaptic pathology …
manifestations, including psychiatric symptoms, indicating a significant synaptic pathology …
ADMINISTRATION OF LEVODOPA IN A PARKINSON'S PATIENT USING A NOVEL ORAL AND MAXILLOFACIAL ROUTE–A FIRST IN HUMAN STUDY
S Thirunavukarasu, BBV Ramanan, SK Suresh… - medRxiv, 2023 - medrxiv.org
Parkinson's disease is characterized by loss of nigrostriatal dopaminergic neurons in the
brain. Dopamine cannot be administered systemically as a treatment because dopamine …
brain. Dopamine cannot be administered systemically as a treatment because dopamine …
A novel maxillofacial technique to deliver drugs to the visual pathway, the optic nerve and the retina using the glymphatic system
JP Arunachalam, R Rajendran, S Chidambaram… - bioRxiv, 2022 - biorxiv.org
The blood neural barriers are formidable barriers that prevent delivery of drugs into the eye
and the brain. Currently, large biologics are used for treating many diseases of the eye and …
and the brain. Currently, large biologics are used for treating many diseases of the eye and …
Immune Barriers in the Olfactory Mucosa
SA Wellford - 2023 - search.proquest.com
The olfactory mucosa is a unique tissue because it directly connects the outside world to the
central nervous system (CNS). From the apical side of the olfactory epithelium, olfactory …
central nervous system (CNS). From the apical side of the olfactory epithelium, olfactory …